PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9717023

Atrial flutter.

R W Campbell
View original source ↗Export metadata ↓

Abstract

Atrial flutter is a specific electrical entity. It has a now well-established mechanism involving a single macro-re-entrant circuit. Whilst many patients with atrial flutter may develop atrial fibrillation, atrial flutter deserves its own recognition and requires specific management. Acute termination by drugs is possible, although adding pacing improves efficacy. Ibutilide is a new intravenous therapy with considerable efficacy by with a risk of torsade de pointes. For long-term control, radiofrequency ablation is gradually supplanting chronic oral antiarrhythmic strategies.

Explore related subjects

Anti-Arrhythmia AgentsAtrial FlutterCardiac Pacing, ArtificialCatheter AblationElectrocardiographyHeart AtriaHumansPrognosisJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R W Campbell. 1998. Atrial flutter.. https://pubmed.ncbi.nlm.nih.gov/9717023/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Expression and activity of potassium ion channels in human prostate cancer.

Four normal and 79 human prostate cancer (Pca) specimens were examined, by immunohistochemistry, for expression of voltage-gated potassium ion channels. Strong immunostaining (for Kv1.3) was observed in the normal and 47% (37/79) of Pca specimens. Twenty-nine percent (23/79) Pca specimens showed moderate and 24% (19/79) displayed low staining. Three potassium channel-openers at a concentration of 10 microg/mL, minoxidil (47.8 microM), 1-Ethyl-2-benzimidazolinone (EBIO) (61.7 microM) and diazoxide (43.3 microM), increased growth of PC3 cells by 30-50%. Potassium channel-blockers, dequalinium, amiodarone and glibenclamide, caused a dose-dependent, growth inhibition of four human Pca cell lines. Apoptosis occurred within 4h of treatment of PC3 cells with dequalinium (0.5 microg/mL, 0.9 microM), amiodarone (5 microg/mL, 7.3 microM) or glibenclamide (50 microg/mL, 0.1mM).

Anti-Arrhythmia Agents↗
PubMed2002

Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.

In this paper, we present a pharmacophore for QT-prolonging drugs, along with a 3D QSAR (CoMFA) study for a series of very structurally variegate HERG K(+) channel blockers. The blockade of HERG K(+) channels is one of the most important molecular mechanisms through which QT-prolonging drugs increase cardiac action potential duration. Since QT prolongation is one of the most undesirable side effects of drugs, we first tried to identify the minimum set of molecular features responsible for this action and then we attempted to develop a quantitative model correlating the 3D stereoelectronic characteristics of the molecules with their HERG blocking potency. Having considered an initial set of 31 QT-prolonging drugs for which the HERG K(+) channel blocking activity was measured on mammalian transfected cells, we started the construction of a theoretical screening tool able to predict whether a new molecule can interact with the HERG channel and eventually induce the long QT syndrome. This in silico tool might be useful in the design of new drug candidates devoid of the physicochemical features likely to cause the above-mentioned side effect.

Anti-Arrhythmia Agents↗
PubMed2002

High performance liquid chromatography for routine monitoring of serum flecainide.

We developed a simple, rapid, and selective assay method for determination of serum flecainide by using solid phase extraction and reversed phase high performance liquid chromatography (HPLC) equipped with ordinary octadecylsilyl silica (ODS) column and ultraviolet (UV) detector. Serum samples spiked with the internal standard were treated by a disposable C(18)-cartridge to extract flecainide. The flecainide and internal standard were separated on ODS column and were detected with an UV detector set at 298 nm. The mobile phase solvent consisting of 0.1 M 1-pentanesulfonic acid sodium salt, acetonitrile, and acetic acid (250:206:2.5 v/v) was used at the flow rate of 1.0 ml/min. The calibration curve for flecainide was linear at the concentration of 50-1500 ng/ml (r=0.9998). The recoveries of flecainide from serum samples were 92-98%. The coefficient of variations (CVs) for intra- and inter-day assay were 1.3-4.8 and 3.2-6.9%, respectively. The method could be applied to routine monitoring of serum flecainide in the patients with tachyarrhythmia.

Anti-Arrhythmia Agents↗